N-methyl-2-(propan-2-yloxy)ethanamine | 114377-28-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-methyl-2-(propan-2-yloxy)ethanamine
• 英文别名: Methyl[2-(propan-2-yloxy)ethyl]amine；N-methyl-2-propan-2-yloxyethanamine
• CAS: 114377-28-5
• 化学式: C₆H₁₅NO
• mdl: MFCD14646149
• 分子量: 117.191
• InChiKey: RSOOVQCAMBUOOD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• SUBSTITUTED THIOPHENYL URACILS, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS
  申请人：Syngenta Crop Protection AG

  公开号：US20200315174A1

  公开（公告）日：2020-10-08

  The invention relates to substituted thiophenyl uracils of general formula (I) or the salts (I) thereof, wherein the groups in general formula (I) are as defined in the description, and to the use thereof as herbicides, in particular for controlling weeds and/or weed grasses in crops of cultivated plants and/or as plant growth regulators for influencing the growth of crops of cultivated plants.

  本发明涉及取代噻吩基尿嘧啶的通式(I)或其盐(I)，其中通式(I)中的基团如描述中定义，以及作为除草剂，特别是用于控制作物中的杂草和/或杂草草本的用途，以及作为植物生长调节剂用于影响栽培植物作物的生长。
• [EN] COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS<br/>[FR] COMPOSES ET COMPOSITIONS UTILISES COMME INHIBITEURS DE LA CATHEPSINE S
  申请人：NOVARTIS AG

  公开号：WO2006018284A1

  公开（公告）日：2006-02-23

  The present invention relates to the use of a 2-cyanopyrimidine compound of the formula (I), wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and , where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.

  本发明涉及使用式(I)的2-氰基嘧啶化合物，其中R1、R2、R3和X如规范和权利要求中定义的那样，以自由形式或盐形式，并在可能的情况下以互变异构形式，作为猫hepsin S活性的抑制剂。
• Benzamide Compounds
  申请人：Gibson Keith Hopkinson

  公开号：US20080293687A1

  公开（公告）日：2008-11-27

  The invention concerns benzamide compounds of Formula (I), wherein R 1a , R 1b , R 1c , R 2 , R 3 , R 4 , m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of histone deacetylase (HDAC).

  这项发明涉及公式（I）的苯甲酰胺化合物，其中R1a、R1b、R1c、R2、R3、R4、m和n具有描述中定义的任意含义；它们的制备过程，含有它们的药物组合物以及它们在制造用作抗增殖剂的药物时的用途，用于预防或治疗对组蛋白去乙酰化酶（HDAC）抑制敏感的肿瘤或其他增殖性疾病。
• [EN] C-4" POSITION SUBSTITUTED MACROLIDE DERIVATIVE<br/>[FR] DÉRIVÉ DE MACROLIDE SUBSTITUÉ EN POSITION C-4"
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2012115256A1

  公开（公告）日：2012-08-30

  A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).

  一种由化学式（I）表示的大环内酯化合物，对红霉素耐药细菌有效（例如，耐药的肺炎球菌、链球菌和支原体）。
• [EN] HETEROCYCLIC COMPOUNDS USEFUL AS NURR-1 ACTIVATORS<br/>[FR] COMPOSES HETEROCYCLIQUES UTILES EN TANT QU'ACTIVATEURS DE NURR-1
  申请人：NOVARTIS AG

  公开号：WO2004072050A1

  公开（公告）日：2004-08-26

  The present invention relates to compounds of formula (I) : wherein R1 is hydroxy, C1-4 alkoxy ,amino, C1-4 alkyl-amino, di C1-4 alkylamino , benzyloxy or C2-C7 alkanoyl, R2 is C1-4 alkyl, C1-4 alkoxy, C1-4 alkoxy C1-4 alkoxy, CF3, halogen, C1-4alkylamino, di C1-4alkylamino, di C1-4 alkylamino C1-4 alkoxy or N-C1-4 alkoxy C1-4 alkyl-N­-C1-4 alkylamino, N-C1-4 alkyl-piperazinyl, morpholinyl or pyrrolidinyl-C1-4 alkoxy, wherein the C1-4 alkyl radicals in R2 are optionally further substituted by C1-4 alkyl, halogen, cyano, amino, alkoxy or alkylthio, X is N or O, Y is N, O or CH, Z is N or CH, and W is N or CH, provided that (a) R1 is not hydroxy or C1-4 alkoxy when R2 is CF3, X is O, Y is CH, Z is N and W is CH, (b) R1 is not hydroxy or C1-4 alkoxy when R2 is CF3 or chloro, X is N, Y is O, Z is CH and W is CH, (c) R1 is not hydroxy when R2 is CF3, X is O, Y is N, Z is CH and W is CH and (d) X and Y are not simultaneously O, the salts thereof; their preparation, their use and pharmaceutical compositions containing them.

  本发明涉及以下化合物的公式（I）：其中R1是羟基，C1-4烷氧基，氨基，C1-4烷基氨基，二甲基胺基，苄氧基或C2-C7烷酰基，R2是C1-4烷基，C1-4烷氧基，C1-4烷氧基C1-4烷氧基，CF3，卤素，C1-4烷基氨基，二C1-4烷基胺基，二C1-4烷基胺基C1-4烷氧基或N-C1-4烷氧基C1-4烷基-N-C1-4烷基胺基，N-C1-4烷基哌嗪基，吗啉基或吡咯啉基-C1-4烷氧基，其中R2中的C1-4烷基基团可以进一步被C1-4烷基，卤素，氰基，氨基，烷氧基或烷基硫基取代，X是N或O，Y是N，O或CH，Z是N或CH，W是N或CH，但前提是（a）当R2是 ，X是O，Y是CH，Z是N，W是CH时，R1不是羟基或C1-4烷氧基，（b）当R2是 或氯时，X是N，Y是O，Z是CH，W是CH时，R1不是羟基或C1-4烷氧基，（c）当R2是 ，X是O，Y是N，Z是CH，W是CH时，R1不是羟基，（d）X和Y不同时是O，以及它们的盐；它们的制备，其用途以及含有它们的药物组合物。